PCVX – vaxcyte, inc. (US:NASDAQ)
Stock Stats
News
Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 [Yahoo! Finance]
Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
Vaxcyte, Inc. (NASDAQ: PCVX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $14.00 price target on the stock.
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference
Form SCHEDULE 13G/A Vaxcyte, Inc. Filed by: JANUS HENDERSON GROUP PLC
Form SCHEDULE 13G/A Vaxcyte, Inc. Filed by: FMR LLC
Form 4 Vaxcyte, Inc. For: Feb 05 Filed by: Eydelman Mikhail
Form 144 Vaxcyte, Inc. Filed by: Eydelman Mikhail
Form 4 Vaxcyte, Inc. For: Feb 03 Filed by: Wassil Jim
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.